Biotech Values

[DewDiligence]

Re: IRA drug-price “negotiations”

Echoing what JNJ said last week about Stelara and Xarelto (#msg-174768280), AZN said on today’s 2Q24 CC that the IRA price-setting for Farziga starting in 2026 will have “very limited impact.” Exactly what this phrase means is open to interpretation, but the salient point is that IRA price-setting is apparently not going to be as deleterious to drug/biotech companies as some investors feared.